From: A novel gene signature based on five immune checkpoint genes predicts the survival of glioma
Variable | Univariate Cox | Multivariate Cox | ||||
P value | HR | 95% CI for HR | P value | HR | 95% CI for HR | |
Gender | 0.350 | 1.145 | 0.862-1.519 | |||
Age | <0.0001 | 1.073 | 1.061-1.084 | <0.0001 | 1.057 | 1.043-1.072 |
IDH 1 status | <0.0001 | 0.163 | 0.121-0.219 | 0.085 | 0.726 | 0.504-1.045 |
MGMT promoter status | <0.0001 | 0.337 | 0.247-0.461 | 0.067 | 0.712 | 0.494-1.025 |
Grade | <0.0001 | 4.794 | 3.798-6.051 | <0.0001 | 2.071 | 1.538-2.788 |
RiskScore | <0.0001 | 3.182 | 2.682-3.777 | <0.0001 | 2.050 | 1.620-2.593 |
Variable | Univariate Cox | Multivariate Cox | ||||
P value | HR | 95% CI for HR | P value | HR | 95% CI for HR | |
Gender | 0.345 | 1.181 | 0.837-1.666 | |||
Age | <0.0001 | 1.038 | 1.023-1.054 | 0.368 | 1.007 | 0.991-1.023 |
IDH 1 status | <0.0001 | 0.256 | 0.178-0.368 | 0.165 | 0.687 | 0.405-1.167 |
MGMT promoter status | <0.0001 | 0.516 | 0.362-0.736 | 0.077 | 0.706 | 0.480-1.039 |
Grade | <0.0001 | 3.477 | 2.716-4.452 | <0.0001 | 2.513 | 1.850-3.415 |
Chemotherapy | 0.125 | 1.151 | 0.962-1.378 | |||
Radiotherapy | 0.688 | 0.945 | 0.718-1.244 | |||
RiskScore | <0.0001 | >10 | >10 | 0.025 | >10 | >10 |